Recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been widely used after autologous peripheral blood stem cell transplant (APBSCT) in an attempt to reduce the duration of neutropenia, but whether this treatment has any influence on long-term engraftment remains unknown. We have retrospectively analyzed data from breast cancer patients to compare post-APBSCT rhG-CSF administration in terms of the short-term benefit and myeloid marrow regeneration after 1 year. Group A included 10 patients not treated with post-APBSCT rhG-CSF, while groups B and C comprised 15 and 13 patients treated with this drug from days +1 and +6, respectively. No differences among the three groups were found in age, diagnosis, previous chemo-radiotherapy, CD34
A number of reports have indicated that various hematopoietic growth factors, including recombinant human granulocyte colony-stimulating factor (rhG-CSF), GM-CSF, IL-1␣, IL-3 and some growth factor combinations can accelerate engraftment when administered after bone marrow (BM) transplantation. 1 Apart from the risk of relapse, one of the major concerns after high-dose therapy followed by autologous peripheral stem cell transplantation (APBSCT) is the short-term procedure-related toxicity, particularly lifethreatening infections or hemorrhage promoted by delayed engraftment. While there seems to be general consensus on the benefit of rhG-CSF on neutrophil recovery after BMT 2, 3 and APBSCT, [4] [5] [6] [7] [8] and in some cases a reduction in hospital stay as compared to patients receiving placebo, [6] [7] [8] most trials fail to detect any valuable effect of rhG-CSF on platelet recovery, incidence of infectious complications and clinical outcome. [4] [5] [6] [7] 9 It is generally accepted that the main effect of rhG-CSF is to stimulate the formation of mature neutrophilic granulocytes, 10 and for that reason, as during the immediate post-transplant period rhG-CSF responsive late-committed neutrophilic progenitors have not been formed, the administration of early (day +1) vs delayed (day +6) rhG-CSF has no major effects. This has been confirmed in a number of studies analyzing the efficacy of initiating rhG-CSF treatment on day +1 or after day +6 both in BM transplantation, 11 and APBSCT, 9, 12 showing no significant differences between both schedules in neutrophil recovery or in clinical outcome.
Data concerning the short-term adverse effects of rhG-CSF administration (bone and muscle pains, flu-like symptoms, headache, fatigue and nausea), have been extensively reported and may be easily controlled with minor analgesia, rarely requiring discontinuation of rhG-CSF treatment. 13 However, there are currently few data evaluating the potential risk of long-term effects related to rhG-CSF administration, and this issue remains open. 14, 15 In this sense, administration of rhG-CSF during the immediate engraftment period might theoretically affect the infused progenitor pool either by stimulating the egress to peripheral blood or by enhancing their proliferation, potentially leading to a relative loss of precursors with self-renewal capacity and a reduced repopulating ability of the BM.
To evaluate the short-term outcome and long-term engraftment, we have retrospectively analyzed data from three breast cancer patient groups randomly assigned to receive rhG-CSF in the immediate post-transplant period (either from day +1 or +6) and those not having been treated with the cytokine after APBSCT.
Materials and methods

Patient characteristics
Thirty-eight patients who had histologically proven breast cancer (32 stage II or III, and six stage IV) ( [1] [2] [3] [4] [5] . Four patients (one patient each in IIIA and IIIB stages, and two patients in stage IV) had received chest wall radiotherapy prior to transplantation. At the time of mobilization no patient had evidence of disease. Detailed data of patient diagnosis and pre-transplant treatment are shown in Table 1 .
PBPC collection and processing
For mobilization, all 38 patients received rhG-CSF (Filgrastim, Amgen, Thousand Oaks, CA, USA) subcutane- Peripheral blood CD34 + cell concentration was assessed on the day before initiation of mobilization, daily after the second day of rhG-CSF treatment, and in each apheresis product.
Cells were cryopreserved in liquid nitrogen and infused when required through a central venous catether.
Conditioning regimen and post-transplant rhG-CSF administration
All 38 patients received STAMP-V conditioning regimen (cyclophosphamide, 1.5 g/m 2 once daily on days 1-4; carboplatinum, 200 mg/m 2 once daily on days 1-4; thiotepa, 125 mg/m 2 once daily on days 1-4). After transplantation patients were randomly assigned not to receive cytokines (group A, n = 10) or to receive rhG-CSF either from day +1 (group B, n = 15) or from day +6 (group C, n = 13). Post-transplant rhG-CSF was administered using a single, daily, subcutaneous injection at a dose of 5 g/kg/day until WBC count exceeded 10.0 ϫ 10 9 /l.
Post-transplant radiotherapy
Once hematological recovery from PBSCT was achieved, 34 patients were administered local field (thoracic wall plus axilla) radiotherapy (55 Gy) in 30 daily sessions. Four patients (one in group A, two in group B and one in group C, respectively) who received pre-transplantation radio-therapy did not undergo further radiation after transplantation procedure.
Hematopoietic bone marrow evaluation
All patients underwent bone marrow aspiration 2 to 4 weeks before the initiation of the mobilization schedule, and one year after transplantation. Aspirated marrow (4 ml per patient) was resuspended in 1 ml of 199 media (GIBCO, Life Technologies, Paisley, UK) and 1500 IU of 5% sodium heparin. Blood dilution was considered when calculating bone marrow cell concentration.
Processing of samples for immunofluorescence analysis was essentially performed as reported elsewhere. 16 Bone marrow samples were stained with PE-or FITC-conjugated CD34 (HPCA-2), FITC-conjugated CD71 (L01.1) and PEconjugated CD33 (LeuM9). Peripheral blood and apheresis products were incubated with FITC-conjugated CD14 (LeuM3), PE-conjugated CD34, PerCP-conjugated CD45 (HLe1). In all cases, irrelevant isotype controls were used (all monoclonal antibodies were from Becton Dickinson (BD), Mountain View, CA, USA). Erythrocytes were lysed with FACS lysing solution (BD) and after washing with PBS, cells were acquired with a FACScalibur flow cytometer (BD) equipped with a 488 nm laser beam. Fifty thousand mononuclear cells were gated by forward and side scatter signals using the Cell Quest 3.2.1 Software. Data analysis was performed with the Paint-A-Gate Pro Software. CD34
+ /CD14 + , CD34 + /CD45 − events, and cells showing inadequate FSC/SSC characteristics were conveniently excluded from analysis in mobilization samples, and in all cases the percentage of non-specific events was subtracted from positive events in stained samples.
Supportive care
All patients received pneumocystis pneumonia prophylaxis with trimethoprim-sulfamethoxazol until day −1, and a standard prophylactic oral antibiotic, antiviral and antifungal therapy (cyprofloxacin, acyclovir and fluconazol). Patients developing fever during the neutropenic period were treated with an empiric combination of broad-spectrum antibiotics, according to our institutional protocol. Packed red blood cell transfusions were given as required to maintain a hemoglobin Ͼ90 g/l and platelets to maintain a platelet count of Ͼ20 ϫ 10 9 /l. Daily blood counts were performed from initiation of high-dose therapy until hospital discharge.
Statistics
The ANOVA test was used to assess for statistical significant differences among the three groups. To assess for differences between patients receiving or not rhG-CSF (groups B and C vs group A) the Mann-Whitney U test was employed. All results are given as mean Ϯ standard errors of mean (s.e.m.) and range values, except for age, expressed as median and range values. A significance level of P Ͻ 0.05 was chosen.
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Results
Patient characteristics and pre-APBSCT BM analysis
Clinical data for patients enrolled in the study are shown in Table 1 . There were no differences in patient characteristics (age, stage, previous therapy) among the three groups being analyzed.
The mean number of total CD34 + cells in the pre-transplant bone marrow analysis was 178.8 Ϯ 52.9/l for the whole series. In patients not receiving post-transplant rhG-CSF (group A) this number was 225.0 Ϯ 113.5/l, 115.4 Ϯ 44.0/l in those who would start rhG-CSF on day +1 post-APBSCT (group B), and 214.4 Ϯ 125.4/l in patients who started the cytokine on day +6 post-transplant (group C), a difference that was not significant. The concentration of steady-state BM CD34
+ /CD71 Ϫ cells, which has been previously reported as a relevant predictive parameter of CD34 + mobilization in breast cancer patients, 17 was 39.1 Ϯ 14.8/l for the whole series. The concentration of this subset was comparable between groups: 33.0 Ϯ 6.9/l, group A; 24.1 Ϯ 9.4/l, group B; and 57.0 Ϯ 37.8/l, group C (Table 1) . No significant differences were found for the number of nucleated cells among groups: TNC 22.8 Ϯ 5.6 ϫ 10 Table 2 ). The CD34 + cell concentration in the whole collected material was 208.1 Ϯ 20.9/l. Mean CD34 + cell concentrations in the infused material according to the study group were as follows: 175.5 Ϯ 29.8/l, 207.0 Ϯ 45.4 and 234.6 Ϯ 22.9, in groups A, B and C, respectively. The differences in the CD34 + cell concentration in the collected material, or in CD34 + cell yields were not significant between groups.
Engraftment data showed that administration of rhG-CSF (either on day +1 or +6) significantly accelerated neutrophil recovery (ANC Ͼ500/l) as compared with untreated patients (9.6 Ϯ 0.2 days and 10.7 Ϯ 0.4 days, vs 13.2 Ϯ 0.9 days, respectively; P Ͻ 0.0001), while those differences were not significant between groups B and C. There were no significant differences between the three groups in the duration of thrombocytopenia, in RBC or platelet transfusions, in febrile days, days receiving antibiotics or in hospital stay (Table 2) .
BM CD34
+
, CD34
+ /CD33 + , and CD34 + /CD71 Ϫ cell concentration in BM samples 1 year after transplant One year after APBSCT, the 38 patients included in the study were in remission and available for assessment of the quality of bone marrow hematopoietic reconstitution. At that time bone marrow analysis showed a total CD34 + cell concentration of 82.4 Ϯ 14.2/l, for the whole series. A significantly higher bone marrow CD34
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+ cell concentration was observed in those patients who had not received post-APBSCT rhG-CSF, compared to those receiving the cytokine on day +1 or +6 (P = 0.01; Table 3 ). Thus, the 1-year post-APBSCT total CD34
+ cell concentration was 148.0 Ϯ 40.9, 72.5 Ϯ 15.9 and 46.1 Ϯ 9.9, for groups A, B and C, respectively (P = 0.02 for group A vs group B; P = 0.003 for group A vs group C; Table 3 ). However, the number of nucleated cells in bone marrow was comparable: 10.4 Ϯ 1.6, 10.3 Ϯ 1.6 and 11.7 Ϯ 1.7 ϫ 10 9 /l for groups A, B and C, respectively.
We then examined two different subsets of CD34 + cells, 
CD34
+ /CD33 + and CD34 + /CD71 Ϫ , in this analysis. rhG-CSF application on day +1 or +6 was significantly associated with a lower concentration of the myeloid committed CD34
+ /CD33 + cell concentration, compared to mean numbers of this subpopulation in patients not having been treated with the growth factor (P = 0.03). Hence, while for the whole series the mean number of CD34 + /CD33 + cells by day +350 was 51.5 Ϯ 7.5/l, group B presented 42.3 Ϯ 10.3/l, group C 37.8 Ϯ 8.3/l, and group A 83.3 Ϯ 19.0/l (Table 3) . Considering the BM CD34 + /CD71 Ϫ subset, enriched in multipotent hematopoietic progenitors and the most immature myeloid progenitors, 18-21 a trend was observed towards reduced numbers of this subset among rhG-CSF-treated patients (P = 0.06). In this sense, the con-centration of CD34 + /CD71 Ϫ cells in group B patients was 15.1 Ϯ 4.3 /l, a similar number (16.4 Ϯ 4.0/l) in group C individuals, while those not treated with the growth factor exhibited the highest concentration of such progenitors (45.0 Ϯ 17.9/l).
Additional comparisons at 1 year post-APBSCT to bone marrow hematopoietic recovery were made, considering the groups of rhG-CSF-treated (B + C) vs untreated (A) patients. The marrow repopulation of the three subsets studied, ie CD34 + , CD34 + /CD33 + and CD34 + /CD71 Ϫ was significantly enhanced in the group without rhG-CSF, compared to treated subjects (P = 0.04, P = 0.03, and P = 0.03, respectively) ( Table 3 ).
Discussion
In this study, the efficacy of the administration of rhG-CSF following APBSCT was evaluated by comparing three otherwise homogeneous groups of breast cancer patients, autografted with (from day +1 or +6) or without rhG-CSF support. We examined not only the short-term effect of post-transplant treatment with the growth factor, but also the consequences of its administration on the hematopoietic progenitor repopulation of different cell subsets in the BM, 1 year after APBSCT. We hypothesized that during the immediate engraftment period, rhG-CSF would enhance the proliferation and irreversible maturation of a number of the infused progenitors, which might be related to a relative decrease of precursors with self-renewal capacity and to a long-term reduced repopulating ability of the BM. In this study there were no major differences in clinical variables, conditioning regimens, or number of cells transplanted, and patients were randomly assigned to receive or not the cytokine on day +1 or +6. Therefore, no clinical or therapeutic variables, other than rhG-CSF administration would be likely to explain the differences observed in hematological and marrow reconstitution between the patient groups.
Our results confirm that rhG-CSF accelerates neutrophil recovery after APBSCT, and that the 'delayed' application of rhG-CSF has the same impact on the rapidity of myeloid recovery as an 'early' start. 9, 11, 12 The more rapid neutrophilic engraftment seen in patients treated with the cytokine does not relate to differences in the number of febrile days, number of intravenous antibiotic days, number of transfusions, or number of post-reinfusion hospital days. Therefore, due to the lack of significant improvement in immediate clinical outcome, our results confirm those of other investigators that question the need of post-APBSCT rhG-CSF application in breast cancer patients treated with STAMP-V conditioning regimens and growth factorprimed progenitor cells.
A more remarkable finding was the significant association between rhG-CSF administration and the reduced BM repopulation by CD34 [18] [19] [20] [21] Thus, patients who have received post-APBSCT rhG-CSF 'early' or 'late' exhibit lower concentrations of both less committed and more differentiated, progenitors in the BM 1 year after the procedure.
To date, the effects of rhG-CSF on BM CD34 + subsets have been poorly understood, and studies have been mainly focused on the analysis of progenitors during the administration of the growth factor. In mice, 22 and in normal human volunteers, 23, 24 rhG-CSF administration increases the total number of nucleated BM cells, but nonetheless, the proportion of the more primitive CD34 + CD38 − , CD34 + CD117 − and CD34 + Ia − cell subsets decreases, as well as the total number of CD34 + cells. Interestingly, it was reported that the administration of rhG-CSF for 2 days to stage IV breast cancer patients shifted the BM stem cell balance in favor of differentiation over self-renewal, being theoretically possible, according to the authors that continuing rhG-CSF therapy could exhaust the primitive progenitor compartment. 25 Moreover, in the clinical setting, T cell-depleted rhG-CSF-stimulated BM allogeneic transplant is associated with delayed pancytopenia, suggesting that after a 5-day rhG-CSF course, the BM might be populated with sufficient engrafting cells, but be deficient in self-renewing, long-term repopulating cells. 26 Our data favor the hypothesis that early post transplant, in the context of a reduced number of very immature hematopoietic progenitors, rhG-CSF might provoke a reduction in the stem cell pool, caused by their stimulation to enter the cell cycle and to irreversible differentiation towards the CFU-GEMM and later maturation stages, and/or their sudden egress into the intravascular pool. This effect does not seem to be clinically relevant when a sufficient number of CD34 + cells are transplanted, as the neutrophil counts in peripheral blood 1 year after the procedure are not significantly different between patients who have received post-APBSCT rhG-CSF and those not being treated with the growth factor (data not shown). However, under stress circumstances, ie sepsis or re-mobilization, the reduced proliferation ability of progenitors might lead to a poor cell number increase.
In conclusion, while the use of rhG-CSF following APBSCT in breast cancer patients does not relate to any obvious clinical short-term benefit other than on neutrophil recovery, its administration could have a significant impact on long-term BM repopulation; although more studies are necessary to evaluate the BM long-term consequences of post-APBSCT rhG-CSF administration in different settings, and with CFU-GEMM evaluation. These observed detrimental effects should be considered particularly in transplantation procedures with low stem cell dose grafts, or when a repeated mobilization for a double transplant is planned or might eventually be required.
